Ligand Pharma CEO reports charitable gift of 130 common shares

Ligand Pharmaceuticals Inc. Chief Executive Officer and director Todd C. Davis reported a bona fide gift of 130 shares of common stock on 12/04/2025.

Rhea-AI Filing Summary

Ligand Pharmaceuticals Inc. Chief Executive Officer and director Todd C. Davis reported a bona fide gift of 130 shares of common stock on 12/04/2025.

The shares were given to a charitable entity and are reported at a price of $0.0, reflecting the gift nature of the transaction. Following this transfer, Davis directly beneficially owns 161,337 shares of Ligand common stock.

Insider Trade Summary

130 shares gifted

Gift 1 txn

Insider Davis Todd C

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	130	$0.00	$0.00

Holdings After Transaction: Common Stock — 161,337 shares (Direct)

Footnotes (1)

1. F1. Represents a bona fide gift of shares to a charitable entity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LGND report in this Form 4?

The filing reports that Todd C. Davis, Chief Executive Officer and director of Ligand Pharmaceuticals Inc., made a bona fide gift of 130 shares of common stock on 12/04/2025.

How many LGND shares did the CEO gift and at what reported price?

Todd C. Davis gifted 130 shares of Ligand Pharmaceuticals Inc. common stock, reported at a price of $0.0 per share, consistent with a charitable gift.

How many LGND shares does Todd C. Davis hold after the reported transaction?

After the reported gift, Todd C. Davis beneficially owns 161,337 shares of Ligand Pharmaceuticals Inc. common stock in direct ownership.

What is the relationship of the reporting person to Ligand Pharmaceuticals (LGND)?

The reporting person, Todd C. Davis, is both a Director and an Officer, serving as Chief Executive Officer of Ligand Pharmaceuticals Inc.

Was the LGND insider transaction a sale for value or a gift?

The transaction is described as a bona fide gift of shares to a charitable entity, with Transaction Code "G" and a reported price of $0.0 per share.

Is this LGND Form 4 filed by one or multiple reporting persons?

The document indicates that the Form is filed by one reporting person, referring to Todd C. Davis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/08/2025 - 07:37 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Todd C

(Last) (First) (Middle)

555 HERITAGE DRIVE

SUITE 200

(Street)

JUPITER FL 33458

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC [ LGND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/04/2025		G		130	D	$0.0(1)	161,337	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a bona fide gift of shares to a charitable entity.

	By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.